RT Journal Article
SR Electronic
T1 Use of fibrin sealants for the localized, controlled release of cefazolin
JF Canadian Journal of Surgery
JO CAN J SURG
FD Canadian Medical Association
SP 347
OP 352
VO 49
IS 5
A1 Stephen Tredwell
A1 John K. Jackson
A1 Donald Hamilton
A1 Vivian Lee
A1 Helen M. Burt
YR 2006
UL http://canjsurg.ca/content/49/5/347.abstract
AB Background: Fibrin sealants are used increasingly in surgery to reduce bleeding and improve wound healing. They have great potential as biocompatible, biodegradable drug delivery systems, because the sealant may adhere to the target tissue and allow controlled release of the drug over an extended period. We investigated the encapsulation, stability and controlled release of erythromycin and cefazolin from Beriplast fibrin sealants (Aventis Behring Canada).Methods: Drug-loaded clots were cast in glass vials and allowed to set. We observed the clots for drug precipitation and aggregation, and we assessed the effect of drug encapsulation on clot strength. Drug stability and release from the clots in phosphate buffered saline (PBS) was quantified by ultraviolet and visible violet absorbance spectroscopy and high-performance liquid chromatography.Results: Erythromycin was found to release slowly from the fibrin clots over the first 2 hours but then degrade rapidly. Cefazolin was found to be very stable in clots in PBS (97% stable at 2 d and 93% stable at 5 d). The drug released in a controlled manner over 2 days, with most being released during the first day. The dose of drug released could be varied by changing the amount placed in the thrombin solution. Clot thickness had no effect on the rate of cefazolin release.Conclusion: Overall, the 2-day release profile and the excellent stability of the drug suggest that cefazolin-loaded fibrin sealants may offer an effective route of postoperative antibiotic delivery.